Free Trial
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Pasithea Therapeutics logo
$0.79 -0.03 (-3.71%)
Closing price 03:50 PM Eastern
Extended Trading
$0.82 +0.02 (+3.16%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Advanced

Key Stats

Today's Range
$0.79
$0.83
50-Day Range
$0.68
$0.90
52-Week Range
$0.65
$4.87
Volume
89,293 shs
Average Volume
96,349 shs
Market Capitalization
$5.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Pasithea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

KTTA MarketRank™: 

Pasithea Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pasithea Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pasithea Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pasithea Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pasithea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.82% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 44.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pasithea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pasithea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.82% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 44.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pasithea Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pasithea Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for KTTA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Pasithea Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 23.92% of the stock of Pasithea Therapeutics is held by institutions.

  • Read more about Pasithea Therapeutics' insider trading history.
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KTTA Stock News Headlines

Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.5% - Here's Why
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More Headlines

KTTA Stock Analysis - Frequently Asked Questions

Pasithea Therapeutics' stock was trading at $3.15 at the beginning of the year. Since then, KTTA stock has decreased by 74.9% and is now trading at $0.79.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) issued its earnings results on Thursday, August, 14th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Shares of Pasithea Therapeutics reverse split on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share.

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
8/14/2025
Today
10/09/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KTTA
CIK
1841330
Fax
N/A
Employees
3
Year Founded
2020

Profitability

EPS (Trailing Twelve Months)
($7.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.90 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-88.60%
Return on Assets
-81.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.97
Quick Ratio
4.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.60 per share
Price / Book
0.07

Miscellaneous

Outstanding Shares
7,440,000
Free Float
7,243,000
Market Cap
$5.88 million
Optionable
Not Optionable
Beta
0.27

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:KTTA) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners